In accordance with applicable privacy legislation, the company Kedrion S.p.a., controller of the data acquired via this website, hereby informs the user that said website does not use profiling cookies to send advertising messages tuned to preferences expressed when browsing the internet. This website installs third party cookies. Continuing to browse, including by scrolling down and clicking on website elements, equates to consent.
For more information, also as regards the technical cookies used by the website and to refuse consent to the installation of individual cookies, please refer to the complete cookies disclosure.
You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES
HIGHLIGHTS
EVENTS
Kedrion keeps Hemophilia therapy debate flowing in Latin America
A recent CLAHT Congress symposium restates current and future role of replacement therapy
read moreCORPORATE
FSI SGR enters Kedrion share capital
The company continues with its growth and development strategy
read more-
CORPORATE - 25-08-2017
Kedrion Biopharma and Kamada Ltd Receive FDA Approval for KEDRAB®
The product is approved for post-exposure prophylaxis against rabies infection
read more -
EVENTS - 14-07-2017
Kedrion Biopharma attends XXVI ISTH Congress in Berlin, Germany
A crowded symposium dedicated to the SIPPET Study was held on July 9th
read more -
EVENTS - 22-05-2017
Farmindustria roadshow is hosted by Kedrion
Innovation and Production of Value held on 19th May at our Bolognana production plant
read more -
EVENTS - 27-04-2017
Kedrion Biopharma joins IPOPI in celebrating World PI Week 2017
Global campaign to improve early diagnosis and optimal treatments for PID
read more
Pages
For more information please contact: pressoffice@kedrion.com
Where 